Ceritinib: a Review in ALK-Positive Advanced NSCLC
Author:
- 3 October 2016
- journal article
- review article
- Published by Springer Nature in Targeted Oncology
- Vol. 11 (5) , 693-700
Abstract
Ceritinib (Zykadia™) is an oral, selective inhibitor of the anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase which, after genetic rearrangement, acts as an oncogenic driver in a proportion of non-small cell lung cancers (NSCLCs). The drug is approved in several countries worldwide for the treatment of patients with ALK-positive, advanced NSCLC who have previously received the first-generation ALK inhibitor crizotinib (indication details may vary by country). Approval was based on its clinical benefit in this setting in the phase I and II trials known as ASCEND-1 and −2. Across these noncomparative studies, 36–56 % of patients achieved a response with ceritinib (at the recommended dosage of 750 mg once daily) and the responses were durable, lasting up to a median of 10 months. Patients survived free from progression for a median of up to 7 months and had a median overall survival of up to 17 months. Moreover, efficacy outcomes in patients with brain metastases were generally consistent with those of the overall study populations. Ceritinib has an acceptable tolerability profile, with gastrointestinal issues, fatigue and liver test abnormalities being the most common adverse reactions. Thus, ceritinib is a valuable treatment option for patients with ALK-positive advanced NSCLC who have already received crizotinib therapy.Keywords
This publication has 23 references indexed in Scilit:
- FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung CancerClinical Cancer Research, 2015
- Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyondOncoTargets and Therapy, 2015
- Activity of second‐generation ALK inhibitors against crizotinib‐resistant mutants in an NPM‐ALK model compared to EML4‐ALKCancer Medicine, 2015
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor AlectinibClinical Cancer Research, 2014
- Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitorsClinical Epidemiology, 2014
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2014
- Ceritinib: First Global ApprovalDrugs, 2014
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung CancerCancer Discovery, 2014
- Ceritinib inALK-Rearranged Non–Small-Cell Lung CancerNew England Journal of Medicine, 2014
- Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical TrialsJournal of Medicinal Chemistry, 2013